RegeneRx to Hold Business Update Conference Call Today at 11:00 A.M. ET – Reminder

ROCKVILLE, Md.--(BUSINESS WIRE)-- RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) advises that investors are reminded of the Company’s business update call today at 11:00 a.m. Eastern time.

To access the conference call, from the U.S. please dial (866) 900-2647 and from outside the U.S. please dial (706) 758-3362. All listeners should provide the following passcode: 59585417. Individuals interested in listening to the live conference call via the Internet may do so at the Company’s website, www.regenerx.com.

A telephone replay will be available through April 27, 2011, by dialing (800) 642-1687 from the U.S. or (706) 645-9291 from outside of the U.S. All listeners should provide the following passcode: 59585417.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via StreetEvents (www.streetevents.com), a password-protected event management site.

RegeneRx (www.regenerx.com) is focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tβ4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development and has an extensive worldwide patent portfolio covering its product candidates.



CONTACT:

Investors:
Lippert/Heilshorn & Associates
Kim Golodetz, 212-838-3777
[email protected]

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.